ArticleThrombosis journal2015
Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.
Article in Thrombosis journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 96 citations in OpenAlex.
- Objective coagulation assays for thrombotic risk stratification in peripheral artery disease: are we ready for clinical translation?International journal of surgery (London, England) · 2026Article
- Haemostatic changes during CART cell therapy and risk of complications.Cancer immunology, immunotherapy : CII · 2026Article
- Marstacimab, an antitissue factor pathway inhibitor, combined with bypassing agents: effects on thrombin generation and in hemostatically normal rats.Research and practice in thrombosis and haemostasis · 2025Article
- Status quo of hypercoagulation as a prognostic indicator following neoadjuvant immunochemotherapy in locally advanced gastric cancer.World journal of gastrointestinal oncology · 2025Review
- Machine learning-based prediction model for arteriovenous fistula thrombosis risk: a retrospective cohort study from 2017 to 2024.BMC nephrology · 2025Article
- Thromboelastometry (ROTEM) Assessing Hypercoagulability in Patients Referred for Thrombophilia Screening.International journal of laboratory hematology · 2025Article
- Severely Ill COVID-19 Patients May Exhibit Hypercoagulability Despite Escalated Anticoagulation.Journal of clinical medicine · 2025Article
- Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis.Clinical and experimental medicine · 2024Article
- Advances in Platelet-Dysfunction Diagnostic Technologies.Biomolecules · 2024Review
- Hemostasis assessment in Fontan patients using the new thrombodynamics test.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023Article
- Review
- Risk stratification for pregnancy-associated venous thromboembolism: Potential role for global coagulation assays.Obstetric medicine · 2022Review
- Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model.Research and practice in thrombosis and haemostasis · 2022Article
- Integral and Local Methods for the Evaluation of the Hemostasiological Profile in Sheep at Various Stages of Implantation of a Biodegradable Vascular Graft.Sovremennye tekhnologii v meditsine · 2022Article
- Emerging Microfluidic Approaches for Platelet Mechanobiology and Interplay With Circulatory Systems.Frontiers in cardiovascular medicine · 2021Review
- Hypercoagulation detected by routine and global laboratory hemostasis assays in patients with infective endocarditis.PloS one · 2021Observational
- Predictive value of combining the level of fibrinogen and antithrombin III for contrast-induced nephropathy in coronary artery disease patients undergoing percutaneous coronary intervention.Biomedical reports · 2020Article
- Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation.Journal of thrombosis and thrombolysis · 2020Article
- Article
- Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism.Biochemia medica · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombosis is a deadly malfunctioning of the hemostatic system occurring in numerous conditions and states, from surgery and pregnancy to cancer, sepsis and infarction. Despite availability of antithrombotic agents and vast clinical experience justifying their use, thrombosis is still responsible for a lion's share of mortality and morbidity in the modern world. One of the key reasons behind this is notorious insensitivity of traditional coagulation assays to hypercoagulation and their inability to evaluate thrombotic risks; specific molecular markers are more successful but suffer from numerous disadvantages. A possible solution is proposed by use of global, or integral, assays that aim to mimic and reflect the major physiological aspects of hemostasis process in vitro. Here we review the existing evidence regarding the ability of both established and novel global assays (thrombin generation, thrombelastography, thrombodynamics, flow perfusion chambers) to evaluate thrombotic risk in specific disorders. The biochemical nature of this risk and its detectability by analysis of blood state in principle are also discussed. We conclude that existing global assays have a potential to be an important tool of hypercoagulation diagnostics. However, their lack of standardization currently impedes their application: different assays and different modifications of each assay vary in their sensitivity and specificity for each specific pathology. In addition, it remains to be seen how their sensitivity to hypercoagulation (even when they can reliably detect groups with different risk of thrombosis) can be used for clinical decisions: the risk difference between such groups is statistically significant, but not large.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.